Deciphera Pharmaceuticals, Inc.'s gastrointestinal stromal tumor treatment DCC-2618 secured an orphan drug designation from the European Medicines Agency.
Gastrointestinal stromal tumors are uncommon tumors that start in special cells in the wall of the gastrointestinal tract, also known as the digestive tract.
The treatment has previously received an orphan drug designation from the U.S. Food and Drug Administration.
An orphan drug designation from the EMA allows a pharmaceutical company to benefit from incentives from the EU to develop a medicine for a rare disease.
DCC-2618 is in a phase 1 clinical trial.
